Table 1 Anti TNF agents
From: COVID-19 infection: an overview on cytokine storm and related interventions
| Â | Structure | Cognate ligands | Half life | Dosing | Frequency |
|---|---|---|---|---|---|
Infliximab (Remicade®) | Chimeric (mouse and human)/ whole mAB against TNF | sTNF, tmTNF | 8–10 | Intravenous | Very 8 weeks following loading at 0, 2 and 6 weeks |
Adalimumab (Humira®) | Human whole mAb against TNF | sTNF, tmTNF | 10–14 | Subcutaneous | Every 2 weeks following initial loading |
Golimumab (Simponi®) | Human whole mAb against TNF | sTNF, tmTNF | 12 ± 3 | Subcutaneous | Monthly following initial loading |
Certolizumab | Humanized PEGylated Fab fragment of a mAb against TNF | sTNF, tmTNF | 3 | Subcutaneous | Every 2Â weeks following initial loading |
Etanercept# (Enbrel®) | TNFR2 fused to IgG1 Fc | sTNF, tmTNF, LTα3 | 14 | Subcutaneous | Weekly/twice Weekly |